This post was originally published on this site
The Birmingham-based company’s test helps detect and monitor multiple myeloma, a cancer in a type of white blood cell, and is on track to deliver more than $220 million of revenue in 2022, Thermo Fisher (NYSE:TMO) said.
Thermo Fisher, which makes scientific instruments, expects the transaction to be completed in the first half of 2023 and boost adjusted earnings per share by 7 cents on the first full-year of ownership.
